Oral corticosteroids are associated with significant adverse effects and increased morbidity, however they are a cornerstone for the management of acute asthma attacks and some people require regular maintenance oral corticosteroids. An increased understanding of the heterogeneity of asthma, and improved access to monoclonal antibody therapy presents an opportunity to minimise oral corticosteroids use in people with asthma. This impact case study provides an overview of the work that has been generated through the Centre of Excellence in Treatable Traits around reducing oral corticosteroid use in asthma.
Learn more about our impact here
View or download our impact case study below.
Oral Corticosteroid Use in Asthma: Impact Case Study